Program
petrelintide
Also written as “Petrelintide” and “ZP8396”.
Its studies are mostly in Obesity · Overweight · Renal Insufficiency, led by 2 companies.
Drug pagePetrelintide: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharmaits history only | 71 open or running | phase 2since Oct 25, 2024 | Oct 14, 2021 | Apr 12, 2027phase 1 · NCT07682818 |
| Hoffmann-La Roche | 44 open or running | phase 3since Sep 11, 2026 | May 11, 2026 | Nov 12, 2027phase 2 · NCT07589686 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6849 petrelintide (Zealand)
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Parexel, ICON Clinical Research and ICON.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentRoche develops it with Zealand Pharma, together in the US and Europe; Roche alone elsewhere.Announced Mar 12, 2025 · Source: Roche, Mar 12, 2025
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named petrelintideINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ZP8396
- Mar 12, 2025Roche develops it with Zealand PharmaCo-developmentTogether in the US and Europe; Roche alone elsewhere · announced · Roche
- May 11, 2026First study: phase 2 study in ObesityFirst studyNCT07589686 · 486 planned
- Sep 11, 20263 phase 3 studies in ObesityPhase 3 reachedNCT07843498, NCT07843485, NCT07843472
Ahead
- Nov 12, 2027Primary completion: phase 2 study in ObesityNCT07589686
- Oct 20, 2028Primary completion: phase 3 study in ObesityNCT07843485
- Dec 21, 2028Primary completion: phase 3 study in ObesityNCT07843498
- Jul 28, 2030Primary completion: phase 3 study in ObesityNCT07843472
TargetBeta
“Petrelintide is a long-acting amylin analog in development for weight management.”study text, by rule · the study
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| eloralintide | Eli Lilly | phase 3 | 26 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 4 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07843472Obesity · United States, Taiwan, United Kingdom | 3 | Recruiting | Jul 28, 2030 | 2,500 |
| NCT07843498Obesity · United States | 3 | Recruiting | Dec 21, 2028 | 3,900 |
| NCT07843485Obesity · United States | 3 | Recruiting | Oct 20, 2028 | 600 |
| NCT07589686Obesity | 2 | Not yet recruiting | Nov 12, 2027 | 486 |
How it is read
Names in the registry
- “Petrelintide”, 9 entries
- “ZP8396”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Overweight, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.